Workflow
第十一批国家组织药品集采报量启动—— 优化规则满足群众多元用药需求
Jing Ji Ri Bao·2025-08-17 21:54

Core Viewpoint - The recent launch of the 11th batch of national organized drug procurement emphasizes the importance of accurate reporting by medical institutions, introducing new rules to enhance flexibility and meet diverse medication needs [1][2]. Group 1: Reporting Rules and Requirements - The new reporting rules include an option for reporting by brand name, allowing medical institutions to cater to diverse patient needs while avoiding a one-size-fits-all approach [1][2]. - The reporting period for this batch is from August 6 to August 25, and all public and military medical institutions are required to participate [1][2]. - Medical institutions can report quantities either by drug name or by brand, with no limit on the number of brands that can be reported [1][2]. Group 2: Demand Estimation and Compliance - Medical institutions must consider clinical demand changes and ensure that total reported quantities are not less than 80% of the average procurement volume for 2023 and 2024 [2][3]. - Institutions are allowed to adjust reported quantities based on actual needs, especially for drugs with expected decreases in usage due to departmental changes or temporary needs [3]. - For drugs not covered by basic medical insurance, such as special or international medical services, they can be excluded from the reporting scope [3]. Group 3: Procurement and Supply Management - If a reported brand is not selected, the corresponding quantity will be managed by the province's main supply enterprise, and institutions must fulfill the agreement quantity with that enterprise [2][3]. - Institutions are encouraged to prioritize selected drugs but are not restricted to them, allowing for flexibility in procurement based on actual clinical needs [3][4]. - Since 2018, a total of 435 drugs have been procured through 10 batches of national organized procurement, which has facilitated the inclusion of 530 new drugs in the national medical insurance directory [3][4]. Group 4: Principles and Market Conduct - The procurement process will adhere to principles of maintaining clinical stability, ensuring quality, preventing collusion, and avoiding market saturation [4]. - Companies are advised to conduct cost-benefit analyses and engage in rational pricing while resisting illegal practices such as collusion and bid-rigging [4].